Sodium glucose co-transporter 2 inhibitors: A novel approach to the management of type 2 diabetes mellitus

Journal of the American Association of Nurse Practitioners

Volumn 26, Issue 7, 2014, Pages 356-363

  Davis, Courtney S ^a   Fleming, Joshua W ^a   Warrington, Laurie E ^a  

^a UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

Canagliflozin; Dapagliflozin; SGLT2 inhibitors; Sodium glucose co transporter 2 inhibitors

Indexed keywords

2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; CANAGLIFLOZIN; GLUCOSIDE; SODIUM GLUCOSE COTRANSPORTER 2;

DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; HUMAN; UNITED STATES;

BENZHYDRYL COMPOUNDS; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; SODIUM-GLUCOSE TRANSPORTER 2; UNITED STATES;

EID: 84904392325     PISSN: 23276886     EISSN: 23276924     Source Type: Journal    
DOI: 10.1002/2327-6924.12135     Document Type: Article

References (50)

1. Amori, R. E., Lau, J., & Pittas, A. G. (2007). Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis. Journal of the American Medical Association, 298(2), 194-206. doi:10.1001/jama.298.2.194
2. TM (dapagliflozin) now approved in European Union for treatment of type 2 diabetes. Retrieved from http://www.astrazeneca.com/Media/Press-releases/Article/20121114--forxiga-eu-approval-type-2-diabetes.
3. Bailey, C. J., Gross, J. L., Hennicken, D., Iqbal, N., Mansfield, T. A., & List, J. F. (2013). Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: A randomized, double-blind, placebo-controlled 102-week trial. BMC Medicine, 11(43), 1-10. doi:10.1186/1741-7015-11-43
4. Bailey, C. J., Gross, J. L., Pieters, A., Bastien, A., & List, J. F. (2010). Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, double-blind, placebo-controlled trial. Lancet, 375(9733), 2223-2233. doi:10.1016/S0140-6736(10)60407-2
5. Bailey, C. J., Iqbal, N., T'joen, C., & List, J. F. (2012). Dapagliflozin monotherapy in drug-naive patients with diabetes: A randomized-controlled trial of low-dose range. Diabetes, Obesity & Metabolism, 14(10), 951-959. doi:10.1111/j.1463-1326.2012.01659.x
6. Bailey, C. J., & Turner, R. C. (1996). Metformin. New England Journal of Medicine, 334(9), 574-579. doi:10.1056/NEJM199602293340906
7. Bennett, W. L., Maruthur, N. M., Singh, S., Segal, J. B., Wilson, L. M., Chatterjee, R., ... Bolen, S. (2011). Comparative effectiveness and safety of medications for type 2 diabetes: An update including new drugs and 2-drug combinations. Annals of Internal Medicine, 154(9), 602-613. doi:10.1059/0003-4819-154-9-201105030-00336
8. Blickle, J. F. (2006). Meglitinide analogues: A review of clinical data focused on recent trials.Diabetes & Metabolism, 32(2), 113-120.
9. Bristol-Myers Squibb. (2014). Forxiga® [package insert]. Retrieved from http://packageinserts.bms.com/pi/pi_farxiga.pdf.
10. Centers for Disease Control and Prevention(CDC) and U.S. Department of Health and Human Services. (2011). Centers for Disease Control and Prevention. National diabetes fact sheet: National estimates and general information on diabetes and prediabetes in the United States, 2011. Retrieve, http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf., 2011
11. Cefalu, W. T., Leiter, L. A., Yoon, K., Arias, P., Niskanen, L., Xie, J., ... Meininger, G. (2013). Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet, 382(9896), 941-950. doi:10.1016/S0140-6736(13)60683-2
12. Clar, C., Gill, J. A., Court, R., & Waugh, N. (2012). Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open, 2(5), 1-12. doi:10.1136/bmjopen-2012-001007
13. Danaei, G., Finucane, M. M., Lu, Y., Singh, G. M., Cowan, M. J., Paciorek, C. J., ... Ezzati, M. (2011). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: Systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet, 378(9785), 31-40. doi:10.1016/S0140-6736(11)60679-X
14. Devineni, D., Morrow, L., Hompesch, M., Skee, D., Vandebosch, A., Murphy, J., ... Schwartz, S. (2012). Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes, Obesity & Metabolism, 14(6), 539-545. doi:10.1111/j.1463-1326.2012.01558.x
15. Doupis, J., & Veves, A. (2008). DPP4 inhibitors: A new approach in diabetes treatment. Advances in Therapy, 25(7), 627-643. doi:10.1007/s12325-008-0076-1
16. Food and Drug Administration(FDA). (2011). FDA briefing document: Dapagliflozin tablets 5 mg and 10 mg. Retrieved from http://www.fda.gov/downloads/advisorycommittees/%20committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm262994.pdf.
17. Food and Drug Administration (FDA). (2013). FDA briefing document. Invokana™ (canagliflozin) tablets. Retrieved from http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolic-DrugsAdvisoryCommittee/UCM334550.pdf.
18. Ferrannini, E., Ramos, S. J., Salsali, A., Tang, W., & List, J. F. (2010). Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: A randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care, 33(10), 2217-2224. doi:10.2337/dc10-0612
19. Fonseca, V. A., Handelsman, Y., & Staels, B. (2010). Colesevelam lowers glucose and lipid levels in type 2 diabetes: The clinical evidence. Diabetes, Obesity & Metabolism, 12(5), 384-392. doi:10.1111/j.1463-1326.2009.01181.x
20. Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., ... Davidson, M. H. (2013). AACE comprehensive diabetes management algorithm 2013. Endocrine Practice, 19(2), 327-336.
21. Groop, L. C. (1992). Sulfonylureas in NIDDM. Diabetes Care, 15(6), 737-754.
22. Janssen Pharmaceuticals. (2013). Invokana™ [package insert]. Retrieved from http://www.invokanahcp.com/prescribing-information.pdf.
23. Kasichayanula, S., Chang, M., Hasegawa, M., Liu, X., Yamahira, N., LaCreta, F. P., ... Boulton, D. W. (2011). Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Diabetes, Obesity & Metabolism, 13(4), 357-365. doi:10.1111/j.1463-1326.2011.01359.x
24. Kasichayanula, S., Liu, X., Shyu, W. C., Zhang, W., Pfister, M., Griffen, S. C., ... Boulton, D. W. (2011). Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes, Obesity & Metabolism, 13(1), 47-54. doi:10.1111/j.1463-1326.2010.01314.x
25. Kerr, J. L., Timpe, E. M., & Petkewicz, K. A. (2010). Bromocriptine mesylate for glycemic management in type 2 diabetes mellitus. Annals of Pharmacotherapy, 44(11), 1777-1785. doi:10.1345/aph.1P271
26. Komala, M. G., Panchapakesan, U., Pollock, C., & Mather, A. (2013). Sodium glucose cotransporter 2 and the diabetic kidney. Current Opinion in Nephrology and Hypertension, 22(1), 113-119. doi:10.1097/MNH.0b013e32835a17ae
27. Komoroski, B., Vachharajani, N., Feng, Y., Li, L., Kornhauser, D., & Pfister, M. (2009). Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clinical Pharmacology and Therapeutics, 85(5), 513-519. doi:10.1038/clpt.2008.250
28. Kurosaki, E., & Ogasawara, H. (2013). Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: Preclinical and clinical data. Pharmacology & Therapeutics, 139(1), 51-59. doi:10.1016/j.pharmthera.2013.04.003
29. Lavalle-González, F. J., Januszewicz, A., Davidson, J., Tong, C., Qiu, R., Canovatchel, W., & Meininger, G. (2013). Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: A randomised trial. Diabetologia, 56(12), 2582-2592. doi:10.1007/s00125013-3039-f1
30. Liu, J. J., Lee, T., & DeFronzo, R. A. (2012). Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes, 61(9), 2199-2204. doi:10.2337/db12-f0052
31. Nainggolan, L. (2013). FDA approves canagliflozin, a first-in-class diabetes drug. Retrieved from http://www.medscape.com/viewarticle/781709.
32. Nauck, M. A., Del Prato, S., Meier, J. J., Duran-Garcia, S., Rohwedder, K., Elze, M., & Parikh, S. J. (2011). Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care, 34(9), 2015-2022. doi:10.2337/dc11-0606
33. NICE. (2013). NICE unable to recommend dapagliflozin for type 2 diabetes and requests more information from the manufacturer. Retrieved from http://www.nice.org.uk/newsroom/pressreleases/NICEUnableRecommendDapagliflozinDiabetes.jsp.
34. Nisly, S. A., Kolanczyk, D. M., & Walton, A. M. (2013). Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes. American Journal of Health-System Pharmacy, 70(4), 311-319. doi:10.2146/ajhp110514
35. Riser Taylor, S., & Harris, K. B. (2013). The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus.Pharmacotherapy, 33(9), 984-999. doi:10.1002/phar.1303
36. Rosenstock, J., Vico, M., Wei, L., Salsali, A., & List, J. F. (2012). Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care, 35(7), 1473-1478. doi:10.2337/dc11-1693
37. Schernthaner, G., Gross, J. L., Rosenstock, J., Guarisco, M., Fu, M., Yee, J., ... Meininger, G. (2013). Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: A 52-week randomized trial. Diabetes Care, 36(9), 2508-2515. doi:10.2337/dc12-2491
38. Selvin, E., Bolen, S., Yeh, H. C., Wiley, C., Wilson, L. M., Marinopoulos, S. S., ... Brancati, F. L. (2008). Cardiovascular outcomes in trials of oral diabetes medications: A systematic review. Archives of Internal Medicine, 168(19), 2070-2080. doi:10.1001/archinte.168.19.2070
39. Stenlof, K., Cefalu, W. T., Kim, K. A., Alba, M., Usiskin, K., Tong, C., ... Meininger, G. (2013). Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes, Obesity & Metabolism, 15(4), 372-382. doi:10.1111/dom.12054
40. Strojek, K., Yoon, K. H., Hruba, V., Elze, M., Langkilde, A. M., & Parikh, S. (2011). Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: A randomized, 24-week, double-blind, placebo-controlled trial. Diabetes, Obesity & Metabolism, 13(10), 928-938. doi:10.1111/j.1463-1326.2011.01434.x
41. Stumvoll, M., Goldstein, B. J., & van Haeften, T. W. (2007). Pathogenesis of type 2 diabetes.Endocrine Research, 32(1-2), 19-37.
42. Thomas, K., & Pollack, A. (2013, March 30). FDA approves new diabetes drug from J and J. New York Times, pp. B4.
43. UKPDS. (1998a). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 352(9131), 854-865.
44. UKPDS. (1998b). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 352(9131), 837-853.
45. van de Laar, F. A., Lucassen, P. L., Akkermans, R. P., van de Lisdonk, E. H., Rutten, G. E., & van Weel, C. (2005). Alpha-glucosidase inhibitors for patients with type 2 diabetes: Results from a Cochrane systematic review and meta-analysis. Diabetes Care, 28(1), 154-163.
46. World Health Organization (WHO). (2011). Global status report on noncommunicable disease 2010. Retrieved from http://www.who.int/nmh/publications/ncd_report_full_en.pdf.
47. Wilding, J. P., Woo, V., Soler, N. G., Pahor, A., Sugg, J., Rohwedder, K., & Parikh, S. (2012). Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: A randomized trial. Annals of Internal Medicine, 156(6), 405-415. doi:10.1059/0003-4819-156-6-201203200-00003
48. Wilding, J. P. H., Charpentier, G., Hollander, P., González-Gálvez, G., Mathieu, C., Vercruysse, F., ... Meininger, G. (2013). Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: A randomised trial. International Journal of Clinical Practice, 67(12), 1267-1282. doi:10.1111/ijcp.12322
49. Yale, J. F., Bakris, G., Cariou, B., Yue, D., David-Neto, E., Xi, L., et al. (2013). Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes, Obesity & Metabolism, 15(5), 463-473. doi:10.1111/dom.12090
50. Yki-Jarvinen, H. (2004). Thiazolidinediones. New England Journal of Medicine, 351(11), 1106-1118. doi:10.1056/NEJMra041001